151 related articles for article (PubMed ID: 38318173)
21. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
22. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
23. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
24. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.
Wu J; Song Y; Su L; Xu L; Chen T; Zhao Z; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Li X; Ouyang X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T; Feng J
BMC Cancer; 2016 Jul; 16():537. PubMed ID: 27460571
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
26. Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
Liang Y; Liu X; Yang J; Wang H; Piao Y; Wei L; Wang L
Chin Med J (Engl); 2023 Jan; 136(2):167-175. PubMed ID: 36780421
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
Sun JJ; Liu L; Wang JR; Shen YZ; Qi TK; Wang ZY; Tang Y; Song W; Chen J; Zhang RF
Chin Med J (Engl); 2020 Dec; 133(23):2796-2802. PubMed ID: 33273327
[TBL] [Abstract][Full Text] [Related]
29. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.
Xie W; Zhou D; Hu K; Xiao X; Huang W; He J; Shi J; Luo Y; Zhang J; Lin M; Cai Z; Huang H; Ye X
Exp Ther Med; 2013 Jul; 6(1):109-114. PubMed ID: 23935730
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
[No Abstract] [Full Text] [Related]
31. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
32. HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.
Wei Z; Zou S; Li F; Cheng Z; Li J; Wang J; Wang C; Chen F; Cao J; Cheng Y
Med Oncol; 2014 Mar; 31(3):845. PubMed ID: 24469952
[TBL] [Abstract][Full Text] [Related]
33. A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Kim DY; Kim YR; Suh C; Yoon DH; Yang DH; Park Y; Eom HS; Lee JO; Kwak JY; Kang HJ; Hyun SY; Jo JC; Chang MH; Yoo KH; Lim SN; Shin HJ; Kim WS; Kim IH; Kim MK; Kim HJ; Lee WS; Mun YC; Kim JS
Am J Gastroenterol; 2023 Aug; 118(8):1373-1380. PubMed ID: 36728217
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
[TBL] [Abstract][Full Text] [Related]
35. Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007-2015.
Morrison VA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Galaznik A
J Geriatr Oncol; 2020 Jan; 11(1):41-54. PubMed ID: 31416716
[TBL] [Abstract][Full Text] [Related]
36. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
38. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
[TBL] [Abstract][Full Text] [Related]
39. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
Nowakowski GS; Hong F; Scott DW; Macon WR; King RL; Habermann TM; Wagner-Johnston N; Casulo C; Wade JL; Nagargoje GG; Reynolds CM; Cohen JB; Khan N; Amengual JE; Richards KL; Little RF; Leonard JP; Friedberg JW; Kostakoglu L; Kahl BS; Witzig TE
J Clin Oncol; 2021 Apr; 39(12):1329-1338. PubMed ID: 33555941
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]